Signed, sealed and delivered, Metsera is finally Pfizer’s. Pfizer has completed its acquisition of the obesity biotech, ...

Pfizer Inc (NYSE:PFE) is preparing to broaden its presence in the global obesity market, with a particular emphasis on ...

Pfizer Inc. ($PFE) is returning to the U.S. debt markets with a fresh corporate bond offering aimed at raising at least $5 ...

“No need for a reunion show: This seasons Real Housewives of Biopharma comes to a close with Pfizer’s winning bid for Metsera ...

Pfizer beats Q3 estimates, raises FY guidance, acquires Metsera for obesity drugs, and offers a 7% yield. Read here for an ...

Pfizer on Thursday closed its up to $10 billion acquisition of Metsera after winning shareholder approval, gaining a foothold ...

The announcement of the deal signaled an end to the bidding war for Metsera between Pfizer and Novo Nordisk, the Danish maker ...

Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of Metsera, Inc. (NASDAQ: MTSR), a ...

Pfizer will pay $86.25 a share in cash, a premium of 3.69% to Metsera's Friday close, according to Metsera's statement. The ...

Pfizer has won a $10 billion deal to acquire obesity drug developer Metsera, securing foothold in lucrative weight-loss ...

The bidding war between Pfizer ( PFE) and Novo Nordisk ( NVO) over obesity drug developer Metsera ( MTSR) finally ended over ...